Dashboard
Manage Tickers

GANXGain Therapeutics, Inc.

Nasdaq gaintherapeutics.com


$ 2.51 $ 0.04 (1.59 %)    

Friday, 31-May-2024 15:54:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ -0.84 (-0.19 %)
DIA $ 398.57 $ 6.05 (1.59 %)
SPY $ 530.36 $ 4.76 (0.91 %)
TLT $ 91.26 $ 0.61 (0.68 %)
GLD $ 225.37 $ -1.27 (-0.59 %)
$ 2.55
$ 2.54
$ 0.00 x 0
$ 0.00 x 0
$ 2.51 - $ 2.54
$ 2.00 - $ 5.33
192,223
na
45.85M
$ 0.88
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-26-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-23-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-25-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-gain-therapeutics-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on Gain...
05/31/2024 10:19:16

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $9 pr...

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
05/30/2024 12:07:00

gain-therapeutics-says-late-breaking-abstract-with-new-data-on-gt-02287-has-been-accepted-for-presentation-at-fens-forum-2024
Gain Therapeutics Says Late-Breaking Abstr...
05/30/2024 11:16:55

hc-wainwright--co-reiterates-buy-on-gain-therapeutics-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on Gain...
05/28/2024 10:34:08

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $9 pr...

hc-wainwright--co-reiterates-buy-on-gain-therapeutics-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on Gain...
05/15/2024 11:12:28

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $9 pr...

gain-therapeutics-q1-cash-cash-equivalent-and-marketable-securities-were-127m-with-cash-runway-guidance-into-2025
Gain Therapeutics' Q1 Cash, Cash Equivalen...
05/14/2024 11:37:04

hc-wainwright--co-reiterates-buy-on-gain-therapeutics-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on Gain...
04/25/2024 10:37:56

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $9 pr...

gain-therapeutics-reports-results-from-single-ascending-dose-part-of-phase-1-clinical-trial-of-gt-02287-novel-gcase-targeting-small-molecule-therapy-for-gba1-parkinsons-disease
Gain Therapeutics Reports Results From Sin...
04/24/2024 13:26:06

GT-02287 was generally well tolerated up to and including the highest planned dose level, and there were no serious adverse eve...

oppenheimer-maintains-outperform-on-gain-therapeutics-maintains-9-price-target
Oppenheimer Maintains Outperform on Gain T...
04/23/2024 12:21:50

Oppenheimer analyst Hartaj Singh maintains Gain Therapeutics (NASDAQ:GANX) with a Outperform and maintains $9 price target.

gain-therapeutics-appoints-gene-mack-as-cfo
Gain Therapeutics Appoints Gene Mack As CFO
04/08/2024 13:27:34

silo-pharma-and-3-other-stocks-under-5-insiders-are-buying
Silo Pharma And 3 Other Stocks Under $5 In...
04/02/2024 11:39:09

The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confid...

hc-wainwright--co-reiterates-buy-on-gain-therapeutics-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on Gain...
04/01/2024 11:15:21

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $9 pr...

chardan-capital-reiterates-buy-on-gain-therapeutics-maintains-6-price-target
Chardan Capital Reiterates Buy on Gain The...
03/27/2024 08:38:00

Chardan Capital analyst Keay Nakae reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $6 price target.

gain-therapeutics-q4-eps-029-beats-032-estimate
Gain Therapeutics Q4 EPS $(0.29) Beats $(0...
03/26/2024 13:30:10

Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0...

gain-therapeutics-q4-earnings-insights
Gain Therapeutics: Q4 Earnings Insights
03/26/2024 13:10:05

gain-therapeutics-fy23-eps-171-vs-148-yoy
Gain Therapeutics FY23 EPS $(1.71) Vs $(1....
03/26/2024 12:14:19

2023 Year End Financial ResultsResearch and development (R&D) expenses increased by $3.1 million to $11.5 million for the y...

Core News & Articles
Market-Moving News for March 5th
03/05/2024 13:33:39

APGE: 50% | Apogee Announces Interim Results from Phase 1 Healthy Volunteer Trial for APG777, for the Treatment for Atopic Derm...

gain-therapeutics-initiates--multiple-ascending-dose-part-of-phase-1-clinical-trial-of-gt-02287-gcase-targeting-small-molecule-therapy-for-gba1-parkinsons-disease
Gain Therapeutics Initiates Multiple Asce...
02/27/2024 19:03:25

gain-therapeutics-announces-preclinical-data-demonstrating-gt-02287-restored-motor-function-in-mouse-models-of-parkinsons-disease
Gain Therapeutics Announces Preclinical Da...
02/06/2024 13:08:04

gain-therapeutics-ceo-matthias-alder-issues-letter-to-shareholders
Gain Therapeutics' CEO Matthias Alder Issu...
01/31/2024 13:14:45

Dear Fellow Stockholders,With the start of a new year, I want to take a moment to reflect on Gain's progress over the last ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION